Eugenol: A Novel Therapeutic Agent for the Inhibition of Species Infection

Overview

Journal Front Pharmacol

Date 2022 Aug 26

PMID 36016558

Authors

Mojtaba Didehdar

Zahra Chegini

Aref Shariati

Affiliations

Soon will be listed here.

Abstract

The high occurrence and mortality rates related to candidiasis emphasize the urgent need to introduce new therapeutic approaches to treat this infection. Eugenol, the main phenolic component of and essential oil, has been used to inhibit growth and different virulence factors of , including strains with decreased susceptibility to antifungals, particularly fluconazole. The results showed that this compound could bind to membrane and decrease ergosterol biosynthesis, consequently leading to cell wall and membrane damage. Additionally, eugenol not only reduced germ tube formation, which reduces nutrient absorption from host tissues, but it also increased the levels of lipid peroxidation and reactive oxygen species, which induces oxidative stress and causes high permeability in the fungal cell membrane. Eugenol inhibited cells' adhesion capacity; additionally, this compound inhibited the formation of biofilms and eliminated established biofilms on a variety of surfaces. Furthermore, by disrupting fungal cell integrity, eugenol could boost the entry of the antifungal drugs into the cell, improving treatment efficacy. Therefore, eugenol could be used in the clinical management of various presentations of candidiasis, especially mucocutaneous presentations such as oral and vulvovaginal infections. However, further investigations, including and animal studies, toxicology studies and clinical trials, as well as molecular analysis, are needed to improve formulations and develop novel antifungal agents based on eugenol.

Citing Articles

Dual Drug Loaded Topical Cubosomal Gel Against Candida Albicans: An In Vitro and In Vivo Proof of Concept.

Nath A, Vaiphei K, Kumar A, Basrani S, Jadhav A, Chakravarti R AAPS PharmSciTech. 2025; 26(3):77.

PMID: 40045107 DOI: 10.1208/s12249-025-03070-2.

In Situ Aqueous Spice Extract-Based Antifungal Lock Strategy for Salvage of Foley's Catheter Biofouled with Biofilm Gel.

Sadanandan B, Vijayalakshmi V, Shetty K, Rathish A, Shivkumar H, Gundreddy M Gels. 2025; 11(1).

PMID: 39851994 PMC: 11765466. DOI: 10.3390/gels11010023.

Natural products in the treatment of diabetic foot infection.

Nazari M, Shokoohizadeh L, Taheri M Eur J Med Res. 2025; 30(1):8.

PMID: 39773682 PMC: 11705749. DOI: 10.1186/s40001-024-02255-y.

Potential Involvement of Reactive Oxygen Species in the Bactericidal Activity of Eugenol against Typhimurium.

Aljuwayd M, Olson E, Abbasi A, Rothrock Jr M, Ricke S, Kwon Y Pathogens. 2024; 13(10).

PMID: 39452770 PMC: 11510353. DOI: 10.3390/pathogens13100899.

A poly-δ-decalactone (PDL) based nanoemulgel for topical delivery of ketoconazole and eugenol against .

Dubey P, Kumar A, Vaiphei K, Basrani S, Jadhav A, Wilen C Nanoscale Adv. 2024; .

PMID: 39247866 PMC: 11376195. DOI: 10.1039/d4na00176a.

References

KOZAM G . The effect of eugenol on nerve transmission. Oral Surg Oral Med Oral Pathol. 1977; 44(5):799-805. DOI: 10.1016/0030-4220(77)90390-5. View

Khan A, Ahmad A, Akhtar F, Yousuf S, Xess I, Khan L . Induction of oxidative stress as a possible mechanism of the antifungal action of three phenylpropanoids. FEMS Yeast Res. 2010; 11(1):114-22. DOI: 10.1111/j.1567-1364.2010.00697.x. View

Spampinato C, Leonardi D . Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents. Biomed Res Int. 2013; 2013:204237. PMC: 3708393. DOI: 10.1155/2013/204237. View

Rangel M, Aquino S, Lima J, Castellano L, de Castro R . Effect of Blume Essential Oil on spp. Involved in Oral Infections. Evid Based Complement Alternat Med. 2018; 2018:4045013. PMC: 6207861. DOI: 10.1155/2018/4045013. View

Ulanowska M, Olas B . Biological Properties and Prospects for the Application of Eugenol-A Review. Int J Mol Sci. 2021; 22(7). PMC: 8036490. DOI: 10.3390/ijms22073671. View

Lone S, Ahmad A . Inhibitory effect of novel Eugenol Tosylate Congeners on pathogenicity of Candida albicans. BMC Complement Med Ther. 2020; 20(1):131. PMC: 7191809. DOI: 10.1186/s12906-020-02929-0. View

Lopez-Ribot J . Candida albicans biofilms: more than filamentation. Curr Biol. 2005; 15(12):R453-5. DOI: 10.1016/j.cub.2005.06.020. View

Braga P, Dal Sasso M, Culici M, Alfieri M . Eugenol and thymol, alone or in combination, induce morphological alterations in the envelope of Candida albicans. Fitoterapia. 2007; 78(6):396-400. DOI: 10.1016/j.fitote.2007.02.022. View

Tacchini M, Echeverria Guevara M, Grandini A, Maresca I, Radice M, Angiolella L . Mill. from Amazonian Ecuador: Chemical Composition and Biological Activities of Extracts and Their Main Constituents (Eugenol and Rosmarinic Acid). Molecules. 2020; 26(1). PMC: 7796418. DOI: 10.3390/molecules26010084. View

10.

Khan M, Malik A, Ahmad I . Anti-candidal activity of essential oils alone and in combination with amphotericin B or fluconazole against multi-drug resistant isolates of Candida albicans. Med Mycol. 2011; 50(1):33-42. DOI: 10.3109/13693786.2011.582890. View

11.

Lone S, Wani M, Fru P, Ahmad A . Cellular apoptosis and necrosis as therapeutic targets for novel Eugenol Tosylate Congeners against Candida albicans. Sci Rep. 2020; 10(1):1191. PMC: 6985109. DOI: 10.1038/s41598-020-58256-4. View

12.

Wijesinghe G, Rossini de Oliveira T, Maia F, de Feiria S, Barbosa J, Joia F . Efficacy of true cinnamon () leaf essential oil as a therapeutic alternative for biofilm infections. Iran J Basic Med Sci. 2021; 24(6):787-795. PMC: 8487610. DOI: 10.22038/ijbms.2021.53981.12138. View

13.

Shao Y, Wu C, Wu T, Li Y, Chen S, Yuan C . Eugenol-chitosan nanoemulsions by ultrasound-mediated emulsification: Formulation, characterization and antimicrobial activity. Carbohydr Polym. 2018; 193:144-152. DOI: 10.1016/j.carbpol.2018.03.101. View

14.

Chaieb K, Zmantar T, Ksouri R, Hajlaoui H, Mahdouani K, Abdelly C . Antioxidant properties of the essential oil of Eugenia caryophyllata and its antifungal activity against a large number of clinical Candida species. Mycoses. 2007; 50(5):403-6. DOI: 10.1111/j.1439-0507.2007.01391.x. View

15.

Doke S, Raut J, Dhawale S, Karuppayil S . Sensitization of Candida albicans biofilms to fluconazole by terpenoids of plant origin. J Gen Appl Microbiol. 2014; 60(5):163-8. DOI: 10.2323/jgam.60.163. View

16.

Hipolito T, Bastos G, Lemos Barbosa T, de Souza T, Coelho L, Dias A . Synthesis, activity, and docking studies of eugenol-based glucosides as new agents against Candida sp. Chem Biol Drug Des. 2018; 92(2):1514-1524. DOI: 10.1111/cbdd.13318. View

17.

Hoyer L, Cota E . Candida albicans Agglutinin-Like Sequence (Als) Family Vignettes: A Review of Als Protein Structure and Function. Front Microbiol. 2016; 7:280. PMC: 4791367. DOI: 10.3389/fmicb.2016.00280. View

18.

Wu X, Cheng A, Sun L, Sun S, Lou H . Plagiochin E, an antifungal bis(bibenzyl), exerts its antifungal activity through mitochondrial dysfunction-induced reactive oxygen species accumulation in Candida albicans. Biochim Biophys Acta. 2009; 1790(8):770-7. DOI: 10.1016/j.bbagen.2009.05.002. View

19.

Sharifzadeh A, Shokri H . In vitro synergy of eugenol on the antifungal effects of voriconazole against Candida tropicalis and Candida krusei strains isolated from the genital tract of mares. Equine Vet J. 2020; 53(1):94-101. DOI: 10.1111/evj.13268. View

20.

El-Baz A, Mosbah R, Goda R, Mansour B, Sultana T, Dahms T . Back to Nature: Combating Biofilm, Phospholipase and Hemolysin Using Plant Essential Oils. Antibiotics (Basel). 2021; 10(1). PMC: 7830859. DOI: 10.3390/antibiotics10010081. View